FDA Brief

Warning letters Drugs

FDA warning letter to

Lydia Co. Ltd.

LowIssued Jun 26, 2023Posted Jul 4, 2023Center for Drug Evaluation and Research | CDER

Lydia Co. Ltd. submitted mismatched drug listing data for eight products, leading FDA to remove them from its NDC Directory.

What happened

FDA reviewed the firm's drug listing information submitted to its electronic Drug Registration and Listing System (eDRLS) and found contradictions between the labeling and the electronic listing files for eight products. FDA had sent a drug listing deficiency letter dated March 17, 2023, and a data removal email dated May 1, 2023; continued deficiencies led to the products' data being removed from FDA's Online NDC Directory. The letter lists mismatches in active ingredients, package quantities, dosage form, and strengths.

What FDA found

  1. For Hot Pap Cataplasma, Amuldy Sports Gel, Zenol Cool, New Hanbang Col Cap, and Nocold-S, the active ingredients in the electronic listing did not match the labeling.

    21 CFR 207.49(a)(4)
  2. For Hot Pap Cataplasma, the listing gave package code (1) for one 13.4 g sheet, but the labeling says the total quantity is 5 sheets.

    21 CFR 207.49(a)(2)
  3. For Antiphlamine, the labeling gives the dosage form as lotion, but the electronic listing says ointment.

    21 CFR 207.49(a)(6)
  4. For Mentholatum, the listing expressed active ingredient strength in milligrams per milliliter while the labeling used milligrams per gram.

    21 CFR 207.49(a)(4)
  5. For Nocold-S, the listing gives chlorpheniramine strength as 200 mg in 20 mL, but the labeling gives 2.5 mg in 20 mL.

    21 CFR 207.49(a)(4)
  6. For Albothyl, the listing gives policresulen strength as 720 mg in 1 mL, but the labeling gives 720 mg/g.

    21 CFR 207.49(a)(4)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of the letter, explaining the specific corrective steps taken and sending related documentation. If corrections cannot be completed in that time, the company must state why and when it will finish.

Who should pay attention

  • drug companies that submit listing data to FDA
  • contract manufacturers and distributors named on NDC listings
  • regulatory staff responsible for eDRLS and NDC Directory accuracy

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk